AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20844233 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag treatment
Number of subjects: 12
Study 20846604 — intervention group
Group type: EXPERIMENTAL
Intervention: Midregional pro-atrial natriuretic peptide (MR-proANP)
Number of subjects: 362
Study 20846604 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MR-proANP and NIHSS
Number of subjects: 362
Study 20846604 — intervention group
Group type: COMPARATOR
Intervention: National Institutes of Health Stroke Scale (NIHSS)
Number of subjects: 362
Study 20846606 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic and diastolic deformation indexes (E(cc) and E(cc)/s)
Number of subjects: 26
Study 20846606 — intervention group
Group type: COMPARATOR
Intervention: Late gadolinium enhancement (LGE)
Number of subjects: 26
Study 20847625 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel colostomy continence device worn for up to 8 hours per day during a 107-day period
Number of subjects: 26
Study 20847625 — intervention group
Group type: COMPARATOR
Intervention: Usual pouching for 21 days
Number of subjects: 26
Study 20847625 — intervention group
Group type: COMPARATOR
Intervention: Wafer transition for 14 days
Number of subjects: 26
Study 20847625 — intervention group
Group type: EXPERIMENTAL
Intervention: Device wear for 107 days
Number of subjects: 26
Study 20851481 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless telemonitoring system via mobile phone network
Number of subjects: 30
Study 20851682 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg daily in 4-week cycles)
Number of subjects: 37
Study 20851928 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype 1
Number of subjects: 96
Study 20851928 — intervention group
Group type: COMPARATOR
Intervention: Haplotype 2
Number of subjects: 96
Study 20851928 — intervention group
Group type: COMPARATOR
Intervention: Haplotype 3
Number of subjects: 96
Study 20851928 — intervention group
Group type: EXPERIMENTAL
Intervention: Luciferase expression with haplotype 1
Number of subjects: 96
Study 20851928 — intervention group
Group type: COMPARATOR
Intervention: Haplotypes 2 and 3
Number of subjects: 96
Study 20854181 — intervention group
Group type: EXPERIMENTAL
Intervention: H1-Coil repetitive transcranial magnetic stimulation (rTMS) at 20 Hz, 2 s on, 20 s off, totaling 1680 stimuli, daily for four weeks
Number of subjects: 19
Study 20854181 — intervention group
Group type: EXPERIMENTAL
Intervention: H1-Coil rTMS
Number of subjects: 19
Study 20854821 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl methionine (SAMe) 1600 mg daily for 2 weeks followed by peginterferon and ribavirin for 48 weeks
Number of subjects: 24
Study 20854821 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alfa-2a and ribavirin for 2 weeks (baseline/control)
Number of subjects: 24
Study 20855799 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir-ritonavir, 600/100 mg twice daily, plus an investigator-selected optimized background regimen
Number of subjects: 429
Study 20856802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (CTLA4-blocking antibody)
Number of subjects: 0
Study 20856865 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic biopsies from PD patients
Number of subjects: 39
Study 20857372 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic radiofrequency ablation (RFA)
Number of subjects: 50
Study 20857372 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session focal RFA
Number of subjects: 50
Study 20858492 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD
Number of subjects: 400
Study 20858492 — intervention group
Group type: EXPERIMENTAL
Intervention: NASH
Number of subjects: 400
Study 20858686 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal VLDL-TG secretion in diabetic men
Number of subjects: 22
Study 20858686 — intervention group
Group type: COMPARATOR
Intervention: Basal VLDL-TG secretion in healthy men
Number of subjects: 22
Study 20858686 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamp VLDL-TG secretion in diabetic men
Number of subjects: 22
Study 20858686 — intervention group
Group type: COMPARATOR
Intervention: Clamp VLDL-TG secretion in healthy men
Number of subjects: 22
Study 20858686 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal VLDL-TG clearance in diabetic men
Number of subjects: 22
Study 20858686 — intervention group
Group type: COMPARATOR
Intervention: Basal VLD-TG clearance in healthy men
Number of subjects: 22
Study 20858686 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamp VLDL-TG clearance in diabetic men
Number of subjects: 22
Study 20858686 — intervention group
Group type: COMPARATOR
Intervention: Clamp VLDL-TG clearance in healthy men
Number of subjects: 22
Study 20858686 — intervention group
Group type: EXPERIMENTAL
Intervention: VLDL-TG FA oxidation during hyperinsulinemia in diabetic men
Number of subjects: 22
Study 20858686 — intervention group
Group type: EXPERIMENTAL
Intervention: VLDL-TG storage in abdominal fat in diabetic men
Number of subjects: 22
Study 20858686 — intervention group
Group type: COMPARATOR
Intervention: VLDL-TG storage in healthy men
Number of subjects: 22
Study 20859106 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 20859150 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 3.9 g/d for up to 5 days per menstrual cycle through six cycles
Number of subjects: 115
Study 20859150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 20859150 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 115
Study 20859612 — intervention group
Group type: COMPARATOR
Intervention: Participants born at term and small for gestational age
Number of subjects: 4744
Study 20859612 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in birthweight by 1 kg
Number of subjects: 4744
Study 20859612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponderal index at birth
Number of subjects: 4744
Study 20859612 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birthweight
Number of subjects: 4744
Study 20859612 — intervention group
Group type: EXPERIMENTAL
Intervention: Prematurity
Number of subjects: 4744
Study 20859612 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthweight z-scores
Number of subjects: 4744
Study 20860020 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin treatment
Number of subjects: 473
Study 20861505 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium plus potassium dietary intervention
Number of subjects: 1906
Study 20862748 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg orally, once daily, on Schedule 4/2
Number of subjects: 321
Study 20862748 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 321
Study 20863431 — intervention group
Group type: EXPERIMENTAL
Intervention: octagam 10% 1 g/kg/day on two consecutive days; maximum infusion rate of 0·12 ml/kg/minute
Number of subjects: 116
Study 20869813 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping drinking motives at 12 months
Number of subjects: 324
Study 20869813 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline victimisation
Number of subjects: 324
Study 20869813 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-related problems at 12 months
Number of subjects: 324
Study 20871389 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI-containing regimens (including zidovudine, tenofovir, or stavudine)
Number of subjects: 757
Study 20871389 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI-sparing regimens (haplogroup W)
Number of subjects: 757
Study 20874659 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alkaline phosphatase (ALP)
Number of subjects: 233
Study 20874659 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage body fat
Number of subjects: 233
Study 20874659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex hormone-binding globulin
Number of subjects: 233
Study 20874659 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cell count
Number of subjects: 233
Study 20874827 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide LY6K-177, peptide TTK-567, and CpG-7909 (level-1; 0, level-2; 0.02, level-3; 0.1 mg/kg)
Number of subjects: 9
Study 20875102 — intervention group
Group type: EXPERIMENTAL
Intervention: IDD-3 (8 doses of autologous monocyte-derived matured DC with GM-CSF and IL-13, pulsed with melanoma cell line lysates, matured with interferon gamma)
Number of subjects: 33
Study 20876174 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction model for invasive candidiasis
Number of subjects: 1515
Study 20876174 — intervention group
Group type: COMPARATOR
Intervention: Clinician judgment
Number of subjects: 1515
Study 20876174 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive candidiasis
Number of subjects: 1515
Study 20876174 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive blood culture
Number of subjects: 1515
Study 20876174 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive urine culture
Number of subjects: 1515
Study 20876174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate comparison
Number of subjects: 1515
Study 20876174 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of candida
Number of subjects: 1515
Study 20876174 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially modifiable risk factors
Number of subjects: 1515
Study 20876373 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli (fecal flora)
Number of subjects: 555
Study 20876373 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS (nasal flora)
Number of subjects: 555
Study 20876373 — intervention group
Group type: EXPERIMENTAL
Intervention: α-hemolytic streptococci (pharyngeal flora)
Number of subjects: 555
Study 20876373 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall resistance
Number of subjects: 555
Study 20876373 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for E. coli
Number of subjects: 555
Study 20876373 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for CNS
Number of subjects: 555
Study 20876373 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for pharyngeal streptococci
Number of subjects: 555
Study 20876670 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental water intake prescribed to achieve a mean urine osmolality of 285 ± 45 mosm/kg
Number of subjects: 8
Study 20877297 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 1914
Study 20877297 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram/Escitalopram (SSRIs)
Number of subjects: 1914
Study 20877651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab
Number of subjects: 0
Study 20877651 — intervention group
Group type: EXPERIMENTAL
Intervention: Outer retinal thickness
Number of subjects: 0
Study 20877651 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodegeneration
Number of subjects: 0
Study 20877651 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoreceptor layer lesions
Number of subjects: 0
Study 20878175 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal increased FAF (Group 1, 31 cases)
Number of subjects: 63
Study 20878175 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal decreased FAF (Group 2, 32 cases)
Number of subjects: 63
Study 20879830 — intervention group
Group type: EXPERIMENTAL
Intervention: Bergen Psychosis Project (BPP) patients
Number of subjects: 218
Study 20879830 — intervention group
Group type: COMPARATOR
Intervention: Nord-Trøndelag Health Study 1995-97 (HUNT2) subjects
Number of subjects: 218
Study 20879880 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced chemotherapy (4 cycles for favorable features, 8 cycles for unfavorable features)
Number of subjects: 479
Study 20879880 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced chemotherapy
Number of subjects: 479
Study 20879963 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy
Number of subjects: 54
Study 20880595 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted partial intracapsular tonsillectomy and adenoidectomy (PITA)
Number of subjects: 30
Study 20880595 — intervention group
Group type: COMPARATOR
Intervention: Bovie electrocautery complete tonsillectomy and adenoidectomy (T&A)
Number of subjects: 30
Study 20881025 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis system on
Number of subjects: 27
Study 20881025 — intervention group
Group type: COMPARATOR
Intervention: Residual native vision (system off)
Number of subjects: 27
Study 20881067 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue α-tocopherol concentrations measured in adipose tissue samples
Number of subjects: 8
Study 20881067 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue triglyceride concentrations
Number of subjects: 8
Study 20881067 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue cholesterol concentrations
Number of subjects: 8
Study 20881264 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB-2914
Number of subjects: 51
Study 20881264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 20881648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary metastasectomy
Number of subjects: 43
Study 20881954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 0
Study 20881954 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (CYP3A specific) with pazopanib
Number of subjects: 0
Study 20881954 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (CYP2C19 specific) with pazopanib
Number of subjects: 0
Study 20881954 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CYP1A2 specific) with pazopanib
Number of subjects: 0
Study 20881954 — intervention group
Group type: EXPERIMENTAL
Intervention: S-warfarin (CYP2C9 specific) with pazopanib
Number of subjects: 0
Study 20881954 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (CYP2D6 specific) with pazopanib
Number of subjects: 0
Study 20883227 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR 80 mg + Lisinopril 40 mg
Number of subjects: 656
Study 20883227 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR 80 mg + Lisinopril 20 mg
Number of subjects: 656
Study 20883227 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR 80 mg + Lisinopril 10 mg
Number of subjects: 656
Study 20883227 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR 40 mg + Lisinopril 40 mg
Number of subjects: 656
Study 20883227 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR 20 mg + Lisinopril 40 mg
Number of subjects: 656
Study 20883227 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR 20 mg + Lisinopril 20 mg
Number of subjects: 656
Study 20883227 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR 40 mg + Lisinopril 20 mg
Number of subjects: 656
Study 20883227 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR 40 mg + Lisinopril 10 mg
Number of subjects: 656
Study 20883227 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol CR 20 mg + Lisinopril 10 mg
Number of subjects: 656
Study 20883227 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol CR 80 mg
Number of subjects: 656
Study 20883227 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 40 mg
Number of subjects: 656
Study 20883586 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring of bipolar parents (O-BD)
Number of subjects: 94
Study 20883586 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring of major depressive disorder (O-UNI)
Number of subjects: 94
Study 20883586 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire group (including O-BD and O-UNI)
Number of subjects: 94
Study 20883586 — intervention group
Group type: COMPARATOR
Intervention: Offspring with no significant psychiatric or medical problems (O-WELL)
Number of subjects: 94
Study 20883929 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dobutamine stress MRI
Number of subjects: 1493
Study 20884191 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 1759
Study 20884191 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 1759
Study 20884379 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS score = 0 (no scar)
Number of subjects: 797
Study 20884379 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS score (scar absence) combined with ejection fraction (≥ 25%)
Number of subjects: 797
Study 20885393 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight children
Number of subjects: 451
Study 20885393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoverweight children
Number of subjects: 451
Study 20885393 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI percentile scores and percent body fat at baseline
Number of subjects: 451
Study 20885393 — intervention group
Group type: EXPERIMENTAL
Intervention: African-American girls
Number of subjects: 451
Study 20885393 — intervention group
Group type: EXPERIMENTAL
Intervention: White boys and girls, African-American boys
Number of subjects: 451
Study 20885393 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimates of obesity and overweight prevalence
Number of subjects: 451
Study 20885982 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive behaviours (RB) classified as tic-like, OCD-like, or mixed based on evaluations using YBOCS symptom checklist and M.I.N.I.
Number of subjects: 166
Study 20885982 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD-like behaviours correlated with higher scores of complex tics, neuroleptic and SSRIs treatment frequency, and less successful socio-professional adaptation.
Number of subjects: 166
Study 20886200 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting bronchodilator (LABD) monotherapy
Number of subjects: 1084
Study 20888065 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-3512676 (0.08, 0.16, 0.24, 0.28, 0.32, or 0.36 mg/kg) administered as 24 weekly subcutaneous injections
Number of subjects: 28
Study 20888065 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-3512676
Number of subjects: 28
Study 20888102 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily extended-release niacin
Number of subjects: 0
Study 20888135 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended model including CEA and IL-6
Number of subjects: 106
Study 20888135 — intervention group
Group type: COMPARATOR
Intervention: Baseline model
Number of subjects: 106
Study 20888135 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort for extended model
Number of subjects: 106
Study 20888135 — intervention group
Group type: COMPARATOR
Intervention: Validation cohort for baseline model
Number of subjects: 106
Study 20889909 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD subjects
Number of subjects: 2118
Study 20889909 — intervention group
Group type: COMPARATOR
Intervention: Smokers without COPD
Number of subjects: 2118
Study 20889909 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers without COPD
Number of subjects: 2118
Study 20890049 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stent technique
Number of subjects: 1668
Study 20890049 — intervention group
Group type: COMPARATOR
Intervention: 2-stent technique
Number of subjects: 1668
Study 20890189 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin at 8 mg/kg intravenously over 30 mins
Number of subjects: 8
Study 20890189 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin at 8 mg/kg every 48 hrs
Number of subjects: 8
Study 20919852 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan AUC of 5800 µmol-min/L
Number of subjects: 36
Study 20919852 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan AUC of 6800 µmol-min/L
Number of subjects: 36
Study 20919852 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan test dose
Number of subjects: 36
Study 20919852 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan conditioning dose 1 pharmacokinetics
Number of subjects: 36
Study 20919852 — intervention group
Group type: COMPARATOR
Intervention: Busulfan standard regimens
Number of subjects: 36
Study 20920156 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (0.5 mg/24 h to 4 mg/24 h, mean daily dose 2.93 ± 1.14 mg/24 h after 2 years)
Number of subjects: 295
Study 20920156 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 295
Study 20920370 — intervention group
Group type: EXPERIMENTAL
Intervention: IV alpha-1 antitrypsin (AAT) augmentation therapy (Alfalastin® or Prolastin®)
Number of subjects: 119
Study 20920370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 20920778 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-4/IL-13 antagonist
Number of subjects: 0
Study 20921437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker generator replacements (cohort 1)
Number of subjects: 1744
Study 20921437 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator generator replacements (cohort 2)
Number of subjects: 1744
Study 20921437 — intervention group
Group type: EXPERIMENTAL
Intervention: Upgrades to or revised cardiac resynchronization therapy device (cohort 2)
Number of subjects: 1744
Study 20921437 — intervention group
Group type: COMPARATOR
Intervention: Cohort 1 (infection rates)
Number of subjects: 1744
Study 20921437 — intervention group
Group type: COMPARATOR
Intervention: Cohort 2 (infection rates)
Number of subjects: 1744
Study 20921541 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based gene expression test for obstructive CAD
Number of subjects: 526
Study 20921879 — intervention group
Group type: EXPERIMENTAL
Intervention: Detected illness
Number of subjects: 265
Study 20921906 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (50 to 100 mg/kg/d)
Number of subjects: 100
Study 20922800 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricoxib 400 mg/day plus erlotinib 150 mg/day
Number of subjects: 20
Study 20922800 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricoxib 100 mg/day
Number of subjects: 20
Study 20922800 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricoxib 200 mg/day
Number of subjects: 20
Study 20922800 — intervention group
Group type: EXPERIMENTAL
Intervention: Apricoxib 400 mg/day
Number of subjects: 20
Study 20922800 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior EGFR-directed therapies
Number of subjects: 20
Study 20922800 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary PGE-M
Number of subjects: 20